{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T02:40:14Z","timestamp":1795142414159,"version":"4.10.3"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"SI2","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes for Health Research","doi-asserted-by":"crossref","award":["381280"],"award-info":[{"award-number":["381280"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008762","name":"Genome Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848006001"],"award-info":[{"award-number":["848006001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,23]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To investigate medication prescription patterns among children with JIA, including duration, sequence and reasons for medication discontinuation.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a single-centre, retrospective analysis of prospective data from the electronic medical records of JIA patients receiving systemic therapy aged 0\u201318\u2009years between 1 April 2011 and 31 March 2019. Patient characteristics (age, gender, JIA subtype) and medication prescriptions were extracted and analysed using descriptive statistics, Sankey diagrams and Kaplan\u2013Meier survival methods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Over a median of 4.2\u2009years follow-up, the 20 different medicines analysed were prescribed as monotherapy (n\u2009=\u200915) or combination therapy (n\u2009=\u200948 unique combinations) among 236 patients. In non-systemic JIA, synthetic DMARDs were prescribed to almost all patients (99.5%), and always included MTX. In contrast, 43.9% of non-systemic JIA patients received a biologic DMARD (mostly adalimumab or etanercept), ranging from 30.9% for oligoarticular persistent ANA-positive JIA, to 90.9% for polyarticular RF-positive JIA. Among systemic JIA, 91.7% received a biologic DMARD (always including anakinra). When analysing medication prescriptions according to their class, 32.6% involved combination therapy. In 56.8% of patients, subsequent treatment lines were initiated after unsuccessful first-line treatment, resulting in 68 unique sequences. Remission was the most common reason for DMARD discontinuation (44.7%), followed by adverse events (28.9%) and ineffectiveness (22.1%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This paper reveals the complexity of pharmacological treatment in JIA, as indicated by: the variety of mono- and combination therapies prescribed, substantial variation in medication prescriptions between subtypes, most patients receiving two or more treatment lines, and the large number of unique treatment sequences.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/keac299","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T12:22:05Z","timestamp":1652876525000},"page":"SI170-SI180","source":"Crossref","is-referenced-by-count":17,"title":["Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis"],"prefix":"10.1093","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6405-6789","authenticated-orcid":false,"given":"Michelle M A","family":"Kip","sequence":"first","affiliation":[{"name":"Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente , Enschede"},{"name":"Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children\u2019s Hospital , Utrecht"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytze","family":"de Roock","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children\u2019s Hospital , Utrecht"},{"name":"Faculty of Medicine, Utrecht University , Utrecht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Currie","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences"},{"name":"Department of Paediatrics, Cumming School of Medicine"},{"name":"Alberta Children\u2019s Hospital Research Institute"},{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-8008","authenticated-orcid":false,"given":"Deborah A","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences"},{"name":"Alberta Children\u2019s Hospital Research Institute"},{"name":"Department of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza R","family":"Grazziotin","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinka","family":"Twilt","sequence":"additional","affiliation":[{"name":"Alberta Children\u2019s Hospital Research Institute"},{"name":"Division of Rheumatology, Department of Pediatrics, Alberta Children\u2019s Hospital, Cumming School of Medicine, University of Calgary , Calgary, Alberta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rae S M","family":"Yeung","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, The Hospital for Sick Children, Department of Paediatrics, Immunology and Institute of Medical Science, University of Toronto , Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-5640","authenticated-orcid":false,"given":"Susanne M","family":"Benseler","sequence":"additional","affiliation":[{"name":"Alberta Children\u2019s Hospital Research Institute"},{"name":"Division of Rheumatology, Department of Pediatrics, Alberta Children\u2019s Hospital, Cumming School of Medicine, University of Calgary , Calgary, Alberta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan J","family":"Vastert","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children\u2019s Hospital , Utrecht"},{"name":"Faculty of Medicine, Utrecht University , Utrecht, The Netherlands"},{"name":"European Reference Network RITA (rare Immunodeficiency Autoinflammatory and Autoimmune Diseases Network)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico","family":"Wulffraat","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children\u2019s Hospital , Utrecht"},{"name":"Faculty of Medicine, Utrecht University , Utrecht, The Netherlands"},{"name":"European Reference Network RITA (rare Immunodeficiency Autoinflammatory and Autoimmune Diseases Network)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2759-2822","authenticated-orcid":false,"given":"Joost F","family":"Swart","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Division of Paediatrics, University Medical Center Utrecht, Wilhelmina Children\u2019s Hospital , Utrecht"},{"name":"Faculty of Medicine, Utrecht University , Utrecht, The Netherlands"},{"name":"European Reference Network RITA (rare Immunodeficiency Autoinflammatory and Autoimmune Diseases Network)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J","family":"IJzerman","sequence":"additional","affiliation":[{"name":"Department of Health Technology and Services Research, Faculty of Behavioural, Management and Social Sciences, Technical Medical Centre, University of Twente , Enschede"},{"name":"Melbourne School of Population and Global Health, University of Melbourne , Parkville, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"2023022318582823300_","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/S0140-6736(11)60244-4","article-title":"Juvenile idiopathic arthritis","volume":"377","author":"Prakken","year":"2011","journal-title":"Lancet"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/acr.23606","article-title":"Trends in population-based incidence and prevalence of juvenile idiopathic arthritis in Manitoba, Canada","volume":"71","author":"Shiff","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.24087","article-title":"Time to treatment as an important factor for the response to methotrexate in juvenile idiopathic arthritis","volume":"61","author":"Albers","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2017.05.007","article-title":"How common is remission in juvenile idiopathic arthritis: systematic review","volume":"47","author":"Shoop-Worrall","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/art.40501","article-title":"Editorial: Toward personalized treatment for systemic juvenile idiopathic arthritis","volume":"70","author":"Vastert","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/23808993.2016.1133234","article-title":"Disease modifying anti-rheumatic drugs in juvenile idiopathic arthritis: striving for individualized therapy","volume":"1","author":"Funk","year":"2016","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.pcl.2018.04.005","article-title":"Systemic juvenile idiopathic arthritis","volume":"65","author":"Lee","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.semarthrit.2016.10.008","article-title":"Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: a systematic review","volume":"46","author":"Davies","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"e001091","DOI":"10.1136\/rmdopen-2019-001091","article-title":"Timing matters: real-world effectiveness of early combination of biologic and conventional synthetic disease-modifying antirheumatic drugs for treating newly diagnosed polyarticular course juvenile idiopathic arthritis","volume":"6","author":"Huang","year":"2020","journal-title":"RMD Open"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/annrheumdis-2017-212104","article-title":"Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis","volume":"77","author":"Swart","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2023022318582823300_","author":"Zorginstituut Nederland","year":"2019"},{"key":"2023022318582823300_","first-page":"2286","article-title":"Etanercept does not essentially increase the total costs of the treatment of refractory juvenile idiopathic arthritis","volume":"31","author":"Haapasaari","year":"2004","journal-title":"J Rheumatol"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/acr.22903","article-title":"Cost-effectiveness analysis of first-line treatment with biologic agents in polyarticular juvenile idiopathic arthritis","volume":"68","author":"Luca","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acr.20337","article-title":"Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease-modifying antirheumatic drugs","volume":"63","author":"Ungar","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association declaration of Helsinki: ethical principles for medical research involving human subjects","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"key":"2023022318582823300_","volume-title":"R: A languange and environment for statistical computing","author":"R Core Team","year":"2019"},{"key":"2023022318582823300_","author":"Wickham","year":"2019"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v040.i03","article-title":"Dates and times made easy with lubridate","volume":"40","author":"Grolemund","year":"2011","journal-title":"J Stat Softw"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"2023022318582823300_","author":"Allaire","year":"2017"},{"key":"2023022318582823300_","author":"Rich","year":"2020"},{"key":"2023022318582823300_","author":"Grazziotin"},{"key":"2023022318582823300_","author":"Nederlandse Vereniging voor Kindergeneeskunde","year":"2017"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1002\/art.38296","article-title":"Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study","volume":"66","author":"Vastert","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1093\/rheumatology\/kez048","article-title":"Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis","volume":"58","author":"Kearsley-Fleet","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1007\/s40273-020-00951-1","article-title":"Simulating progression-free and overall survival for first-line doublet chemotherapy with or without bevacizumab in metastatic colorectal cancer patients based on real-world registry data","volume":"38","author":"Degeling","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12874-021-01211-2","article-title":"A scoping review of studies using observational data to optimise dynamic treatment regimens","volume":"21","author":"Mahar","year":"2021","journal-title":"BMC Med Res Methodol"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13075-020-02408-4","article-title":"The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy","volume":"23","author":"Solomon","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/rheumatology\/ket170","article-title":"Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?","volume":"52","author":"Anink","year":"2013","journal-title":"Rheumatology (Oxford)"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12969-020-0413-7","article-title":"Patient factors associated with waiting time to pediatric rheumatologist consultation for patients with juvenile idiopathic arthritis","volume":"18","author":"Barber","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00296-018-4062-9","article-title":"Juvenile idiopathic arthritis in the biologic era: predictors of the disease progression and need for early introduction of biologic treatment","volume":"38","author":"Nalbanti","year":"2018","journal-title":"Rheumatol Int"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10198-016-0786-1","article-title":"Social\/economic costs and health-related quality of life in patients with juvenile idiopathic arthritis in Europe","volume":"17(Suppl 1)","author":"Kuhlmann","year":"2016","journal-title":"Eur J Health Econ"},{"key":"2023022318582823300_","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1080\/14737167.2021.1857241","article-title":"Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system","volume":"21","author":"Kip","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"2023022318582823300_","author":"UCAN CAN-DU","year":"2021"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keac299\/43923476\/keac299.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI2\/SI170\/49318829\/keac299.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/62\/SI2\/SI170\/49318829\/keac299.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T19:55:47Z","timestamp":1700596547000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/62\/SI2\/SI170\/6588065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":40,"journal-issue":{"issue":"SI2","published-online":{"date-parts":[[2022,5,18]]},"published-print":{"date-parts":[[2023,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keac299","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,5,18]]}}}